Crizotinib associated interstitial pneumonitis

Last revised by David Luong on 6 Feb 2022

Citation, DOI, disclosures and article data

Citation:

Weerakkody Y, Luong D, Bickle I, Crizotinib associated interstitial pneumonitis. Reference article, Radiopaedia.org (Accessed on 18 Apr 2024) https://doi.org/10.53347/rID-92609

DOI:

https://doi.org/10.53347/rID-92609

Permalink:

https://radiopaedia.org/articles/92609

rID:

92609

Article created:

27 Aug 2021, Yuranga Weerakkody ◉

Disclosures:

At the time the article was created Yuranga Weerakkody had no recorded disclosures.

View Yuranga Weerakkody's current disclosures

Last revised:

6 Feb 2022, David Luong ◉

Disclosures:

At the time the article was last revised David Luong had no recorded disclosures.

View David Luong's current disclosures

Revisions:

4 times, by 3 contributors - see full revision history and disclosures

Systems:

Chest

Synonyms:

Crizotinib associated intersitial lung disease
Crizotinib associated intersitial pneumonitis

Crizotinib associated interstitial pneumonitis is a type of drug-induced lung disease precipitated by a tyrosine kinase/anaplastic lymphoma kinase (ALK) inhibitor Crizotinib used in the treatment of certain forms of non-small cell lung cancer that have certain mutations including the ROS1 mutation and the anaplastic lymphoma kinase (ALK) fusion oncogene positivity.

The overall reported incidence of pneumonitis was ~ 2% for all grades ³.

It can occur at any time after commencement of the agents with a median onset of 23 days (range 3-763 days) from the initiation of crizotinib therapy according to one study ¹. Although rare, high mortality rates have been reported¹. Some publications report two forms of lung disease ⁵.

References

1. Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD, Stollenwerk NS. Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials. (2017) Clinical lung cancer. 18 (5): 472-479. doi:10.1016/j.cllc.2017.03.004 - Pubmed
2. Mizuki Nishino, Hiroto Hatabu, Lynette M. Sholl, Nikhil H. Ramaiya. Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. (2017) RadioGraphics. doi:10.1148/rg.2017170015
3. Takeshi Johkoh, Kyung Soo Lee, Mizuki Nishino, William D. Travis, Jay H. Ryu, Ho Yun Lee, Christopher J. Ryerson, Tomás Franquet, Alexander A. Bankier, Kevin K. Brown, Jin Mo Goo, Hans-Ulrich Kauczor, David A. Lynch, Andrew G. Nicholson, Luca Richeldi, Cornelia M. Schaefer-Prokop, Johny Verschakelen, Suhail Raoof, Geoffrey D. Rubin, Charles Powell, Yoshikazu Inoue, Hiroto Hatabu. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. (2021) Radiology. doi:10.1148/radiol.2021203427
4. Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: A comprehensive review. (2013) South Asian journal of cancer. 2 (2): 91-7. doi:10.4103/2278-330X.110506 - Pubmed
5. Wu S, Liu K, Ren F, Zheng D, Pan D. Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report. (2018) BMC pulmonary medicine. 18 (1): 121. doi:10.1186/s12890-018-0682-9 - Pubmed
6. Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review. (2015) Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 10 (8): 1148-55. doi:10.1097/JTO.0000000000000577 - Pubmed